SPECIAL ISSUES

DMD 2014

Drug Metab Dispos. 2014;42:541-5. The role of transporters in toxicity and disease. Schuetz JD, Swaan PW, Tweedie DJ. PubMed

Drug Metab Dispos. 2014;42:546-60. The role of canalicular ABC transporters in cholestasis. Cuperus FJ, Claudel T, Gautherot J, Halilbasic E, Trauner M. PubMed

Drug Metab Dispos. 2014;42:561-5. The roles of MRP2, MRP3, OATP1B1, and OATP1B3 in conjugated hyperbilirubinemia. Keppler D. PubMed

Drug Metab Dispos. 2014;42:586-95. Modeling human nonalcoholic steatohepatitis-associated changes in drug transporter expression using experimental rodent models. Canet MJ, Hardwick RN, Lake AD, Dzierlenga AL, Clarke JD, Cherrington NJ. PubMed

Drug Metab Dispos. 2014;42:596-602. Selective and cytokine-dependent regulation of hepatic transporters and bile acid homeostasis during infectious colitis in mice. Merrell MD, Nyagode BA, Clarke JD, Cherrington NJ, Morgan ET. PubMed

Drug Metab Dispos. 2014;42:623-31. Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy? Callaghan R, Luk F, Bebawy M. PubMed

Drug Metab Dispos. 2014;42:650-64. Understanding the transport properties of metabolites: case studies and considerations for drug development. Zamek-Gliszczynski MJ, Chu X, Polli JW, Paine MF, Galetin A. PubMed

Drug Metab Dispos. 2014;42:665-74. Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile acid transporters multidrug resistance-associated proteins 3 and 4. Köck K, Ferslew BC, Netterberg I, Yang K, Urban TJ, Swaan PW, Stewart PW, Brouwer KL. PubMed

Drug Metab Dispos. 2014;42:675-84. The role of organic anion transporters in diagnosing liver diseases by magnetic resonance imaging. Pastor CM, Müllhaupt B, Stieger B. PubMed